cis-ジアンミン白金(II)ジクロリド

cis-ジアンミン白金(II)ジクロリド 化學(xué)構造式
15663-27-1
CAS番號.
15663-27-1
化學(xué)名:
cis-ジアンミン白金(II)ジクロリド
別名:
cis-ジアンミン白金(II)ジクロリド;ブリプラチン;ランダ;プラチジアム;シスプラチン;cis-ジアンミンジクロロ白金;ジクロロジアンミン白金;ジアンミンジクロロ白金;ジクロロジアンミン白金(II)(シス);CIS-ジクロロジアミン白金(II);cis-ジアンミンジクロロ白金(II);cis-白金(II)ジアンミンジクロリド;(SP‐4‐2)‐ジアンミンジクロロ白金;CIS‐ジクロロジアミン白金(II);CIS-ジアンミン白金(II) ジクロリド;cis-ジクロロジアンミン白金(II), 99% CISPLATINシスプラチン;シスプラチン (JP17)
英語(yǔ)名:
Cisplatin
英語(yǔ)別名:
cddp;cpdd;CIS-PLATINUM;cis-dichlorodiammineplatinum;CIS-DIAMMINEPLATINUM(II) DICHLORIDE;CPDC;cacp;PLATINOL;CISPLATIIN;cisplatine
CBNumber:
CB9236183
化學(xué)式:
Cl2H6N2Pt
分子量:
300.04
MOL File:
15663-27-1.mol
MSDS File:
SDS

cis-ジアンミン白金(II)ジクロリド 物理性質(zhì)

融點(diǎn) :
270 °C (lit.)
比重(密度) :
3,7 g/cm3
貯蔵溫度 :
2-8°C
溶解性:
DMFに可溶灶成。ほとんどの一般的な溶剤に不溶
外見(jiàn) :
結晶性
色:
黃色
水溶解度 :
<0.1 g/100 mL で 19 ºC
Merck :
14,2317
暴露限界値:
ACGIH: TWA 0.002 mg/m3
NIOSH: IDLH 4 mg/m3; TWA 0.002 mg/m3
安定性::
安定。酸化剤、アルミニウム背传、酸化防止剤と相容れない。
CAS データベース:
15663-27-1(CAS DataBase Reference)
IARC:
2A (Vol. 26, Sup 7) 1987, 1 (Vol. 76, 100A) 2012
EPAの化學(xué)物質(zhì)情報:
Cisplatin (15663-27-1)
安全性情報
  • リスクと安全性に関する聲明
  • 危険有害性情報のコード(GHS)
主な危険性  T
Rフレーズ  45-25-41-60-46-42/43-36/37/38
Sフレーズ  53-26-39-45-99-36/37/39-22
RIDADR  UN 3288 6.1/PG 2
WGK Germany  3
RTECS 番號 TP2455000
10-21
TSCA  Yes
HSコード  2843 90 90
國連危険物分類(lèi)  6.1(a)
容器等級  II
有毒物質(zhì)データの 15663-27-1(Hazardous Substances Data)
毒性 LD50 in guinea pigs: 9.7 mg/kg i.p. (Fleishman)
絵表示(GHS) GHS hazard pictogramsGHS hazard pictograms
注意喚起語(yǔ) 危険
危険有害性情報
コード 危険有害性情報 危険有害性クラス 區分 注意喚起語(yǔ) シンボル P コード
H300 飲み込むと生命に危険 急性毒性掷饶、経口 1, 2 危険 GHS hazard pictograms P264, P270, P301+P310, P321, P330,P405, P501
H315 皮膚刺激 皮膚腐食性/刺激性 2 警告 GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H317 アレルギー性皮膚反応を起こすおそれ 感作性、皮膚 1 警告 GHS hazard pictograms P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
H319 強い眼刺激 眼に対する重篤な損傷性/眼刺激 性 2A 警告 GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H334 吸入するとアレルギー、喘息または门扎、呼吸困難 を起こすおそれ 感作性、呼吸器 1 危険 GHS hazard pictograms P261, P285, P304+P341, P342+P311,P501
H335 呼吸器への刺激のおそれ 特定標的臓器毒性、単回暴露脆揉; 気道刺激性 3 警告 GHS hazard pictograms
H350 発がんのおそれ 発がん性 1A, 1B 危険 GHS hazard pictograms
注意書(shū)き
P201 使用前に取扱説明書(shū)を入手すること。
P280 保護手袋/保護衣/保護眼鏡/保護面を著(zhù)用するこ と。
P301+P310 飲み込んだ場(chǎng)合:直ちに醫師に連絡(luò )すること。
P302+P352 皮膚に付著(zhù)した場(chǎng)合:多量の水と石鹸で洗うこと。
P305+P351+P338 眼に入った場(chǎng)合:水で數分間注意深く洗うこと瘾杭。次にコ ンタクトレンズを著(zhù)用していて容易に外せる場(chǎng)合は外す こと。その後も洗浄を続けること。

cis-ジアンミン白金(II)ジクロリド 価格 もっと(39)

メーカー 製品番號 製品説明 CAS番號 包裝 価格 更新時(shí)間 購入
富士フイルム和光純薬株式會(huì )社(wako) W01TRCC499500 シスプラチン
Cisplatin
15663-27-1 50mg ¥16800 2024-03-01 購入
富士フイルム和光純薬株式會(huì )社(wako) W01TRCC499500 シスプラチン
Cisplatin
15663-27-1 500mg ¥40800 2024-03-01 購入
富士フイルム和光純薬株式會(huì )社(wako) W01SRM78-0450 cis-ジクロロジアンミン白金(II), 99% CISPLATINシスプラチン
cis-Dichlorodiammine platinum(II), 99% CISPLATIN
15663-27-1 1g ¥97200 2024-03-01 購入
富士フイルム和光純薬株式會(huì )社(wako) W01LKTC3374 シスプラチン
Cisplatin
15663-27-1 1g ¥67800 2024-03-01 購入
富士フイルム和光純薬株式會(huì )社(wako) W01TRCC499500 シスプラチン
Cisplatin
15663-27-1 250mg ¥20400 2023-06-01 購入

cis-ジアンミン白金(II)ジクロリド MSDS


Cisplatin

cis-ジアンミン白金(II)ジクロリド 化學(xué)特性,用途語(yǔ),生産方法

外観

わずかにうすい黃色?黃色, 結晶性粉末?粉末

溶解性

水に溶けにくく派篱、エタノール及びアセトンにほとんど溶けない。[溶解方法] 0.9% NaCl溶液に0.5mg/mlに溶解。使用時(shí)は実験に使用する溶液で希釈を行う。

解説

シスプラチン,睪丸腫瘍菇肃,膀胱癌,卵巣癌などの化學(xué)療法剤として中心的な薬剤であり缚哪,構造式に白金を含む薬物。しかし,腎毒性や催吐作用など副作用も強いことがネックとなっていた。シスプラチンの副作用を軽減するために,カルボプラチンが開(kāi)発され豫我,日本では 1990年3月に承認が得られた。カルボプラチンは,すでに世界 30ヵ國で使用されており,シスプラチン投與時(shí)に必要な大量の水分負荷が不要なこと,蓄積毒性が少なく継続治療が可能であることから,その治療効果が注目されている储狐。白金錯體 [PtCl2(NH3)2]2+ のシス體.睪丸がん,卵巣がん熄出,乳がんなどに有効であるが,トランス體には抗がん性はない.類(lèi)似白金化合物として,カルボフラチンが臨床に用いられている.DNAに結合し,その複製を阻害する.

用途

様々ながんに使用される細胞増殖抑制剤防苗、抗がん剤

用途

がん研究用試薬。

用途

DNA 鎖內及び鎖間の白金 -DNA 架橋を形成し均唉、DNA の複製及び転寫(xiě)阻 害作用を示します。

効能

抗悪性腫瘍薬, 細胞増殖阻害薬

特徴

平面四配位.シス體,トランス體とも伤极,Pt-Cl 233 pm间癣,Pt-N 201~205 pm

商品名

アイエーコール (日本化薬); ランダ (日本化薬)

使用上の注意

不活性ガス封入

化學(xué)的特性

Cisplatin is a white powder or yellow crystalline solid with the melting point 268-272°C (decomposition). It is slightly soluble in water and easily soluble in dimethylformamide. In aqueous solution, it can be gradually transformed into trans-and hydrolysis.

使用

Cisplatin is a cytostatic agent and it is used to treat various cancer types, including cancer of ovary, testis, lung, head, neck, bladder, neuroblastoma, and nephroblastoma, and Hodgkin’s disease and non-Hodgkin lymphoma.

調製方法

Cisplatin is obtained by the method described by Kauffman and Cowan, in which potassium(II) tetrachloroplatinate is treated with buffered aqueous ammonia solution. Pure cisplatin is obtained by recrystallization from dilute hydrochloric acid.

適応癥

Cisplatin (Platinol) is an inorganic coordination complex with a broad range of antitumor activity. It is especially useful in the treatment of testicular and ovarian cancer. It binds to DNA at nucleophilic sites, such as the N7 and O6 of guanine, producing alterations in DNA structure and inhibition of DNA synthesis. Adjacent guanine residues on the same DNA strand are preferentially cross-linked. This platinating activity is analogous to the mode of action of alkylating agents. Cisplatin also binds extensively to proteins. It does not appear to be phase specific in the cell cycle.

定義

ChEBI: Cisplatin is a diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, D A and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary.

一般的な説明

An anticancer drug. Orange-yellow to deep yellow solid or powder.

空気と水の反応

Insoluble in water.

反応プロフィール

Cisplatin is incompatible with oxidizing agents. Cisplatin is also incompatible with aluminum. Cisplatin may react with sodium bisulfite and other antioxidants.

火災危険

Flash point data for Cisplatin are not available; however, Cisplatin is probably combustible.

応用例(製薬)

CDDP, also referred to as cisplatinum or cisplatin, is a yellow powder and has found widespread use a chemotherapeutic agent.

生物活性

Cisplatin is a platinum-containing compound that acts as a DNA-crosslinking agent and interferes with replication and transcription, culminating in apoptosis. It forms intra- and interstrand crosslinks with DNA with intrastrand guanine-to-guanine or guanine-to-alanine links accounting for the majority of DNA binding. Cisplatin halts the cell cycle at the G2/M phase in vitro and is active against murine tumors transplanted into mice and in mouse xenograft models, including a reduction in tumor growth in a model of squamous cell carcinoma of the head and neck when administered at doses ranging from 7.5 to 12.5 mg/kg. Cisplatin also inhibits the RecA recombinase of M. tuberculosis (IC50 = 2 μM), blocking protein splicing and cell growth. Formulations containing cisplatin have been used, alone and in combination therapy, in the treatment of a variety of cancers.

作用機序

Cisplatin shows biphasic plasma decay with a distribution phase half-life of 25 to 49 minutes and an elimination half-life of 2 to 4 days. More than 90% of the drug is bound to plasma proteins, and binding may approach 100% during prolonged infusion. Cisplatin does not cross the blood-brain barrier. Excretion is predominantly renal and is incomplete.

臨床応用

Cisplatin, combined with bleomycin and vinblastine or etoposide, produces cures in most patients with metastatic testicular cancer or germ cell cancer of the ovary. Cisplatin also shows some activity against carcinomas of the head and neck, bladder, cervix, prostate, and lung.

副作用

Renal toxicity is the major potential toxicity of cisplatin. Severe nausea and vomiting that often accompany cisplatin administration may necessitate hospitalization. Cisplatin has mild bone marrow toxicity, yielding both leukopenia and thrombocytopenia. Anemia is common and may require transfusions of red blood cells. Anaphylactic allergic reactions have been described. Hearing loss in the high frequencies (4000 Hz) may occur in 10 to 30% of patients. Other reported toxicities include peripheral neuropathies with paresthesias, leg weakness, and tremors. Excessive urinary excretion of magnesium also may occur.

安全性プロファイル

Confirmed carcinogen with experimental carcinogenic and tumorigenic data. Poison by ingestion, intramuscular, submtaneous, intravenous, and intraperitoneal routes. Human systemic effects: change in audttory acuity, change in kidney tubules, changes in bone marrow, corrosive to skin, depressed renal function tests, hallucinations, nausea or vomiting. Experimental teratogenic and reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of Cland NOx. See also PLATINUM COMPOUNDS.

職業(yè)ばく露

A potential danger to those involved in the manufacture, formulation and administration of this anticancer chemotherapy agent. Contact with water causes decomposition.

発がん性

Cisplatin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

代謝

It is rapidly hydrated, resulting in a short plasma half-life of less than 30 minutes. It is eliminated predominantly via the kidney, but approximately 10% of a given dose undergoes biliary excretion. It is highly nephrotoxic and can cause significant damage to the renal tubules, especially in patients with preexisting kidney disease or one kidney or who are concurrently receiving other nephrotoxic drugs (e.g., cyclophosphamide or ifosfamide). Dosages should be reduced in any of the above situations. Clearance decreases with chronic therapy, and toxicities can manifest at a late date. To proactively protect patients against kidney damage, patients should be hydrated with chloride-containing solutions. Saline or mannitol diuretics can be administered to promote continuous excretion of the drug and its hydrated analogues. Sodium thiosulfate, which accumulates in the renal tubules, also has been used to neutralize active drug in the kidneys in an effort to avoid nephrotoxicity.

輸送方法

UN2928 Toxic solids, corrosive, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, 8-Corrosive material, Technical Name Required. UN3290 Toxic solid, corrosive, inorganic, n.o.s., Hazard class: 6.1; Labels: 6.1-Poisonous materials, 8-Corrosive material. UN3288 Toxic solids, inorganic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required. UN3249 Medicine, solid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials

純化方法

Recrystallise it from dimethylformamide and check the purity by IR and UV-VIS spectroscopy. [Raudaschl et al. Inorg Chim Acta 78 143 1983.] HIGHLY TOXIC, SUSPECTED CARCINOGEN.

不和合性

Aluminum reacts with cisplatin and decreases the drug’s effectiveness. Do not use any aluminum equipment to prepare or administer cisplatin.

廃棄物の処理

Disposal of unused product must be undertaken by qualified personnel who are knowledgeable in all applicable regulations and follow all pertinent safety precautions including the use of appropriate protective equipment. For proper handling and disposal, always comply with federal, state, and local regulations

參考文獻

G.H.W. Milburn, M.R. Truter, J. Chem. Soc. A, 1966, 1609, DOI: 10.1039/J19660001609.

參考文獻

1) Van Waardenburg et al. (2004), Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin; J. Biol. Chem,, 279 54502 DOI:10.1074/JBC.M410103200
2) Siddik et al. (2003), Cisplatin: mode of cytotoxic action and molecular basis of resistance; Oncogene, 22 7265 DOI:10.1038/sj.onc.1206933
3) Seki et al. (2000), Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma; Cancer Chemother. Pharmacol., 45 199 DOI:10.1007/s002800050030
4) Nomura et al. (2004), Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells; Urol. Oncol., 22 453 DOI:10.1016/J.UROLONC.2004.04.035
5) Raghavan et al. (2015), Dimethylsulfoxide inactivates the anticancer effect of cisplatin against myelogenous leukemia cell lines in in vitro assays.; Indian J. Phamracol., 47 322 DOI:10.4103/0253-7613.157132
6) Synthesis of Essential Drugs (2006, Elsevier) - libgen.lc
7) Sittig's Pharmaceutical Manufacturing Encyclopedia
8) Patty's Toxicology 6-Volume Set-Wiley (2012)
9) Modern pharmacology with clinical applications (2004, LWW)

cis-ジアンミン白金(II)ジクロリド 上流と下流の製品情報

原材料

準備製品


cis-ジアンミン白金(II)ジクロリド 生産企業(yè)

Global( 765)Suppliers
名前 電話(huà)番號 電子メール 國籍 製品カタログ 優(yōu)位度
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.
+86-0531-69954981 +8615666777973
dwyane.wang@boyuanpharm.com China 211 58
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8810 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12839 58
Hebei Chuanghai Biotechnology Co,.LTD
+86-13131129325
sales1@chuanghaibio.com China 5890 58
Shaanxi TNJONE Pharmaceutical Co., Ltd
+8618092446649
sarah@tnjone.com China 1143 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
sales@sjar-tech.com China 444 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21634 55
Hangzhou FandaChem Co.,Ltd.
+8615858145714
FandaChem@Gmail.com China 9204 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070
product@chemlin.com.cn CHINA 3009 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32957 60

cis-ジアンミン白金(II)ジクロリド  スペクトルデータ(1HNMR、FT-IR、MS)


15663-27-1(cis-ジアンミン白金(II)ジクロリド)キーワード:


  • 15663-27-1
  • peyrone’schloride
  • platidiam
  • platidiamlachemabrno
  • tr170
  • cis-Platinous diamine dichloroplatin
  • cis-Diaminedichloroplatinum(II)
  • CISPLATIN (CIS-DICHLORODIAMMINEPLATINUM(II))
  • CIS-DIAMINE PLATINUM-(II)-DICHLORIDE
  • cis-Diamminedichloroplatinum(II), Pt 64.5% min
  • cis-Diammineplatinum(II) dichloride, 99.99%
  • cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin
  • cis-Diammineplatinum(II) dichloride,cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin
  • Cisplatin (100 mg)
  • cis-DIAMMINEDICHLOROPLATINUM (II) 99.999%
  • cis-Dichlorodiamineplatinum(II), (trace metal basis), 99.99%
  • Randa
  • Cisplatin(CDDP)
  • Cisplatin cis-Diamminedichloroplatinum(II) cis-Platinum(II) Diammine Dichloride
  • cis-DichlorodiaMineplatinuM(II), 99.99%, (trace Metal basis)
  • cis-DichlorodiaMineplatinuM(II), 99.99% 250MG
  • cis-DichlorodiaMineplatinuM
  • LEDERPLATIN
  • BRIPLATIN
  • DIAMMINEDICHLOROPLATINATE (II)
  • CISMAPLAT
  • CISPLATIN DIHYDROCHLORIDE
  • CIS PT(NH3)2CL2
  • CISPLATYL
  • CIS-PLATINUM(II)DIAMMINE DICHLORIDE
  • CIS-PLATINUM(II)DIAMINE DIHYDROCHLORIDE
  • cis-ジアンミン白金(II)ジクロリド
  • ブリプラチン
  • ランダ
  • プラチジアム
  • シスプラチン
  • cis-ジアンミンジクロロ白金
  • ジクロロジアンミン白金
  • ジアンミンジクロロ白金
  • ジクロロジアンミン白金(II)(シス)
  • CIS-ジクロロジアミン白金(II)
  • cis-ジアンミンジクロロ白金(II)
  • cis-白金(II)ジアンミンジクロリド
  • (SP‐4‐2)‐ジアンミンジクロロ白金
  • CIS‐ジクロロジアミン白金(II)
  • CIS-ジアンミン白金(II) ジクロリド
  • cis-ジクロロジアンミン白金(II), 99% CISPLATINシスプラチン
  • シスプラチン (JP17)
  • 白金化合物
  • 構造分類(lèi)
  • 金屬別化合物
  • 遷移金屬化合物
  • 生化學(xué)
  • 試験研究用抗腫瘍剤
Copyright 2017 ? ChemicalBook. All rights reserved